The Gemigliptin Market Size is valued at USD 1.66 billion in 2022 and is predicted to reach USD 2.65 billion by the year 2031 at a 5.5% CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
Gemigliptin belongs to the class of medicines known as dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors are utilized to treat type 2 diabetes mellitus. These medications function by blocking the enzyme DPP-4, which is responsible for the breakdown of incretin hormones such as GLP-1 (glucagon-like peptide-1). The incidence of type 2 diabetes is a primary driver of diabetic medication demand.
The global Gemigliptin market has been steadily growing owing to the augumented prevalence of diabetes worldwide and the increasing acceptance of effective oral antidiabetic medications. Gemigliptin is expected to acquire popularity in the global market as demand for safer and more convenient diabetes treatment choices develops.However, the pandemic caused havoc in healthcare systems around the world. Patients' ability to get basic medical care, particularly diabetes management, may have been hampered by lockdowns, restricted movement, and overcrowded healthcare facilities. This may have an impact on the prescription and use of drugs such as gemigliptin.
The Gemigliptin Market is segmented on the basis of type of drug, dosage form, distribution channel, end-user, application, and patient demographics. Type of drug includes Gemigliptin Monotherapy and Gemigliptin Combination Therapy. The dosage form segment includes Gemigliptin Tablets and Gemigliptin Injectable. Distribution channel includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The end-user segment includes Hospitals, Clinics and Outpatient Facilities, and Homecare Settings. By application, the market is segmented into Type 2 diabetes and Prediabetes. Based on patient demographics, the market is segmented into Adult Population and Geriatric Population.
The Type 2 diabetes category is expected to hold a significant share of the global Gemigliptin Market in 2022. The worldwide rise of type 2 diabetes prevalence creates a larger patient pool needing efficient treatment alternatives. This rising need may propel the market for drugs such as gemigliptin. The efficacy of gemigliptin and other DPP-4 inhibitors in controlling blood glucose levels is a major market driver. Positive clinical trial data confirming their ability to lower HbA1c levels and enhance glycemic management may persuade physicians to prescribe these drugs.
The adult population segment is projected to grow at a rapid rate in the global Gemigliptin Market. The raised prevalence of type 2 diabetes in the adult population raises the need for effective treatments. Ageing can have an impact on glucose metabolism and insulin sensitivity. Medications like gemigliptin, which targets the underlying processes of diabetes, can aid in managing blood sugar levels in this population. Gemigliptin is one of the diabetes treatment choices accessible, and its popularity is tied to the growing number of adults diagnosed with the disease.
The North America Gemigliptin Market is projected to register the highest market share in terms of revenue shortly due to the region's high prevalence of type 2 diabetes. With a huge diabetic population and a well-established healthcare system, the United States, in particular, is a key contributor to the market. The availability of excellent medical facilities and favorable reimbursement policies for diabetes medications promote the growth of the Gemigliptin market in North America.
Furthermore, Asia Pacific is expected to rise rapidly over the forecast period, owing to an increasing diabetic population in countries such as China, India, and Japan. The region's vast population, urbanization, and changing lifestyles have resulted in an alarming surge in diabetes incidence. As the region's healthcare infrastructure improves and diabetes management knowledge grows, the need for effective oral antidiabetic drugs such as Gemigliptin is likely to rise.
| Report Attribute | Specifications |
| Market size value in 2022 | USD 1.66 Bn |
| Revenue forecast in 2031 | USD 2.65 Bn |
| Growth rate CAGR | CAGR of 5.5 % from 2023 to 2031 |
| Quantitative units | Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Type of Drug, By Dosage Form, By Distribution Channel, By End-User, By Patient Demographics |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | LG Chem, Hanmi Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd., Novartis AG, EirGenix, Inc., Biocon Limited, G.L. Pharma GmbH, Daewoong Pharmaceutical Co., Ltd., Sandoz International GmbH, Boryung Pharmaceutical Co., Ltd., VHB Life Sciences Limited, HanAll Biopharma, Taiba Healthcare, Huons Co., Ltd., Dong-A ST Co., Ltd. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Gemigliptin Market By Type of Drug-
Gemigliptin Market By Dosage Form-
Gemigliptin Market By Distribution Channel-
Gemigliptin Market By End-User-
Gemigliptin Market By Application-
Gemigliptin Market By Patient Demographics-
Gemigliptin Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gemigliptin Market Snapshot
Chapter 4. Global Gemigliptin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Drug Estimates & Trend Analysis
5.1. By Type of Drug, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Type of Drug:
5.2.1. Gemigliptin Monotherapy
5.2.2. Gemigliptin Combination Therapy
Chapter 6. Market Segmentation 2: By Dosage Form Estimates & Trend Analysis
6.1. By Dosage Form & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Dosage Form:
6.2.1. Gemigliptin Tablets
6.2.2. Gemigliptin Injectable
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis
8.1. By End-User & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-User:
8.2.1. Hospitals
8.2.2. Clinics and Outpatient Facilities
8.2.3. Homecare Settings
Chapter 9. Market Segmentation 5: By Application Estimates & Trend Analysis
9.1. By Application & Market Share, 2020 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:
9.2.1. Type 2 Diabetes
9.2.2. Prediabetes
Chapter 10. Market Segmentation 6: By Patient Demographics Estimates & Trend Analysis
10.1. By Patient Demographics & Market Share, 2020 & 2031
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Patient Demographics:
10.2.1. Adult Population
10.2.2. Geriatric Population
Chapter 11. Gemigliptin Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Type of Drug, 2019-2031
11.1.2. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Dosage Form, 2019-2031
11.1.3. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
11.1.4. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By End-User, 2019-2031
11.1.5. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
11.1.6. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Patient Demographics, 2019-2031
11.1.7. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
11.2. Europe
11.2.1. Europe Gemigliptin Market revenue (US$ Million) By Type of Drug, 2019-2031
11.2.2. Europe Gemigliptin Market revenue (US$ Million) By Dosage Form, 2019-2031
11.2.3. Europe Gemigliptin Market revenue (US$ Million) By Distribution Channel, 2019-2031
11.2.4. Europe Gemigliptin Market revenue (US$ Million) By End-User, 2019-2031
11.2.5. Europe Gemigliptin Market revenue (US$ Million) By Application, 2019-2031
11.2.6. Europe Gemigliptin Market revenue (US$ Million) By Patient Demographics, 2019-2031
11.2.7. Europe Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.3. Asia Pacific
11.3.1. Asia Pacific Gemigliptin Market revenue (US$ Million) By Type of Drug, 2019-2031
11.3.2. Asia Pacific Gemigliptin Market revenue (US$ Million) By Dosage Form, 2019-2031
11.3.3. Asia Pacific Gemigliptin Market revenue (US$ Million) By Distribution Channel, 2019-2031
11.3.4. Asia Pacific Gemigliptin Market revenue (US$ Million) By End-User, 2019-2031
11.3.5. Asia Pacific Gemigliptin Market revenue (US$ Million) By Application, 2019-2031
11.3.6. Asia Pacific Gemigliptin Market revenue (US$ Million) By Patient Demographics, 2019-2031
11.3.7. Asia Pacific Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.4. Latin America
11.4.1. Latin America Gemigliptin Market revenue (US$ Million) By Type of Drug, (US$ Million) 2019-2031
11.4.2. Latin America Gemigliptin Market revenue (US$ Million) By Dosage Form, (US$ Million) 2019-2031
11.4.3. Latin America Gemigliptin Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
11.4.4. Latin America Gemigliptin Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
11.4.5. Latin America Gemigliptin Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
11.4.6. Latin America Gemigliptin Market revenue (US$ Million) By Patient Demographics, (US$ Million) 2019-2031
11.4.7. Latin America Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.5. Middle East & Africa
11.5.1. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Type of Drug, (US$ Million) 2019-2031
11.5.2. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Dosage Form, (US$ Million) 2019-2031
11.5.3. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
11.5.4. Middle East & Africa Gemigliptin Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
11.5.5. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
11.5.6. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Patient Demographics, (US$ Million) 2019-2031
11.5.7. Middle East & Africa Gemigliptin Market revenue (US$ Million) by country, 2019-2031
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. LG Chem,
12.2.2. Hanmi Pharmaceutical Co., Ltd.,
12.2.3. Boryung Pharmaceutical Co., Ltd.,
12.2.4. Novartis AG, EirGenix, Inc.,
12.2.5. Biocon Limited,
12.2.6. G.L. Pharma GmbH,
12.2.7. Daewoong Pharmaceutical Co., Ltd.,,
12.2.8. Sandoz International GmbH,
12.2.9. Boryung Pharmaceutical Co., Ltd.,
12.2.10. VHB Life Sciences Limited,
12.2.11. HanAll Biopharma,
12.2.12. Taiba Healthcare,
12.2.13. Huons Co., Ltd.,
12.2.14. Dong-A ST Co., Ltd.